NCT/Study#

NCT04310592 /

CYNK-001-AML-001

A phase I multi-dose study of human placental hematopoietic stem cell derived natural killer cells (CYNK-001) in adults with ACTIVEly diagnosed primary or secondary acute myeloid leukemia (AML) in morphologic complete remission with minimal residual disease (MRD)

A phase I multi-dose study of human placental hematopoietic stem cell derived natural killer cells (CYNK-001) in adults with ACTIVEly diagnosed primary or secondary acute myeloid leukemia (AML) in morphologic complete remission with minimal residual disease (MRD)

DISEASE GROUP:
Leukemia
current phase:
Phase I
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: